Barriers interfering with establishment of Collaborative Drug Therapy Management (CDTM) agreements between clinical pharmacists and physicians

被引:9
|
作者
Alhossan, Abdulaziz [1 ]
Alazba, Asma [1 ]
机构
[1] King Saud Univ, Dept Clin Pharm, Riyadh, Saudi Arabia
关键词
CDTM; Collaborative Drug Therapy Management; Agreement; Barriers; Clinical pharmacists; Physicians; OUTCOMES; IMPACT; INTERVENTIONS;
D O I
10.1016/j.jsps.2019.04.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The current level of awareness among health care providers towards working under collaborative agreements, and the barriers that interfere with establishing CDTM agreements between clinical pharmacists and physicians were studied. Methods: A structured survey was developed after reviewing the literature on CDTM. The questions were validated to assess the level of awareness regarding the role of clinical pharmacists in providing drug therapy management, and to determine the main barriers for not having collaborative agreements with different specialties. In addition to demographic data, physicians' education background, reasons for not having clinical pharmacy services in their clinics, and their perceptions for signing a collaborative agreement were also collected. The sample for the study was obtained from different health specialties in Saudi Arabia. The validated survey was sent and received within approximately two months, Oct-Nov 2017. Results: We have received 55 responses from different sectors, a 79% response rate. Most physicians had worked before with a clinical pharmacist (76%) and of which 60% valued the services provided by the clinical pharmacist as extremely important and very important (29.1%; 30.9%) respectively. When physicians asked if they have heard about the Collaborative Drug Therapy Management agreement or the term CDTM, 67% of respondents haven't heard that before. Most of the responses, regarding the physicians' awareness of the actual CDTM agreement services, were correct. Only 18% selected incorrect CDTM services. The results showed higher percentages of physicians agreeing with the benefits of CDTM agreement as it can improve overall patient care, reduces risk of drug related adverse events or interactions and allows clinical pharmacists to be part of patient care; 85.5, 83.6 and 83.6 respectively. Physicians who rated the possibility to be involved or to encourage other health care professionals in signing collaborative agreements as high were 76.3 and 74.5 respectively. Based on their specialty, emergency medicine's physicians were most likely to have a CDTM agreement and to encourage others too. On a scale from zero to hundred, the average of the responses rating lack of knowledge about such an agreement as potential barrier on preventing CDTM agreements was 69 +/- 0.30. While the gender barrier had the lowest rating with a mean of 15. Conclusion: There is a huge lack of knowledge and understanding about the role of clinical pharmacists and in CDTM concept. This lack of knowledge affected on having collaborations between clinical pharmacists and physicians in different settings. Educating health care providers and stakeholders about the role of clinical pharmacists in providing drug therapy management and encouraging the concept of CDTM among healthcare providers are the main solutions to enhance clinical pharmacist's role in patient care. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:713 / 716
页数:4
相关论文
共 28 条
  • [1] Clinical pharmacy experience in ophthalmology setting of using collaborative drug therapy management (CDTM)
    Al-Saikhan, Fahad I.
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2015, 22 (06) : 347 - 352
  • [2] Collaborative drug therapy management by pharmacists
    Carmichael, JM
    OConnell, MB
    Devine, B
    Kelly, HW
    Ereshefsky, L
    Linn, WD
    Stimmel, GL
    PHARMACOTHERAPY, 1997, 17 (05): : 1050 - 1061
  • [3] Assessment of diabetic care associated with collaborative practice agreements between clinical pharmacists and physicians.
    Kiel, PJ
    McCord, AD
    Jackson, TL
    PHARMACOTHERAPY, 2003, 23 (10): : 1369 - 1369
  • [4] Collaborative Drug Therapy Management by Pharmacists - 2003
    Hammond, RW
    Schwartz, AH
    Campbell, MJ
    Remington, TL
    Chuck, S
    Blair, MM
    Vassey, AM
    Rospond, RM
    Herner, SJ
    Webb, CE
    PHARMACOTHERAPY, 2003, 23 (09): : 1210 - 1225
  • [5] Collaborative drug therapy modification (CDTM): Facilitators, barriers, and perceptions of individual pharmacist participation in Georgia
    Osae, Sharmon P.
    Palmer, Russ
    Harvey, Ashlee
    Keedy, Chelsea A.
    Lavender, Devin L.
    Phillips, Beth Bryles
    Johnson, Blake R.
    Young, Henry N.
    Stone, Rebecca H.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2024, 64 (03)
  • [6] Using Collaborative Drug Therapy Agreements to Train Student Pharmacists to Provide Clinical Patient Care Services
    McKeirnan, Kimberly C.
    Akers, Julie M.
    Czapinski, Jennifer C.
    Robinson, Jennifer D.
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 2017, 81 (02)
  • [8] Evaluating the costs and benefits of collaborative drug therapy management (CDTM) in a community health center network.
    Melzer, DJ
    Krueger, KP
    Brackett, PD
    PHARMACOTHERAPY, 2003, 23 (10): : 1354 - 1354
  • [9] Improvement of drug treatment in elderly patients, through the collaborative work between pharmacists and physicians
    Mestres, Conxita
    Puerta, Laura
    Hernandez, Marta
    Agusti, Anna
    Llagostera, Blanca
    INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2016, 16
  • [10] Assessment of Assistance in Smoking Cessation Therapy by Pharmacies in Collaboration with Medical Institutions - Implementation of a Collaborative Drug Therapy Management Protocol Based on a Written Agreement between Physicians and Pharmacists
    Watanabe, Fumiyuki
    Shinohara, Kuniko
    Dobashi, Akira
    Amagai, Kenji
    Hara, Kazuo
    Kurata, Kaori
    Iizima, Hideo
    Shimakawa, Kiyoshi
    Shimada, Masahiko
    Abe, Sakurako
    Takei, Keiji
    Kamei, Miwako
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2016, 136 (09): : 1243 - 1254